(NASDAQ: FOLD) Amicus Therapeutics's forecast annual revenue growth rate of 14.77% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 237.23%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.8%.
Amicus Therapeutics's revenue in 2025 is $571,160,000.On average, 5 Wall Street analysts forecast FOLD's revenue for 2025 to be $192,307,463,045, with the lowest FOLD revenue forecast at $191,661,393,317, and the highest FOLD revenue forecast at $193,158,203,717. On average, 5 Wall Street analysts forecast FOLD's revenue for 2026 to be $232,421,118,698, with the lowest FOLD revenue forecast at $229,021,854,882, and the highest FOLD revenue forecast at $236,512,071,670.
In 2027, FOLD is forecast to generate $270,963,678,263 in revenue, with the lowest revenue forecast at $264,161,143,518 and the highest revenue forecast at $278,133,634,341.